Histogen Inc.

Equities

HSTO

US43358Y2028

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 12:06:23 29/05/2024 am IST			5-day change	1st Jan Change
0.17 ^USD	0.00%		0.00%	-44.75%

19/04	Subchapter V Trustee Appointed Under Chapter 11 for Histogen Inc.	CI
18/04	Histogen Inc. Filed for Bankruptcy	CI

Histogen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022

May 13, 2022 at 01:57 am IST

Histogen Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 3.76 million compared to USD 0.431 million a year ago. Net loss was USD 0.673 million compared to USD 4.27 million a year ago. Basic loss per share from continuing operations was USD 0.2 compared to USD 2.8 a year ago.

Latest news about Histogen Inc.

Subchapter V Trustee Appointed Under Chapter 11 for Histogen Inc.	19/04	CI
Histogen Inc. Filed for Bankruptcy	18/04	CI
Histogen Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
Histogen Inc.(OTCPK:HSTO) dropped from NASDAQ Composite Index	04/23/04	CI
Histogen Inc. and Allergan Mutually Elect to Terminate the Amended and Restated License Agreement	04/23/04	CI
Histogen Inc.(NasdaqCM:HSTO) dropped from S&P TMI Index	22/23/22	CI
Wall Street Set to Open Wednesday Trading Higher as Investors Await Fed Decision on Interest Rates	20/23/20	MT
Top Premarket Gainers	20/23/20	MT
Histogen Says Board Approved Complete Liquidation, Dissolution	19/23/19	MT
Histogen Inc. Announces Executive Changes	19/23/19	CI
Histogen Inc. Announces Board and Executive Changes	19/23/19	CI
Histogen Announces Update on Potential Strategic Alternatives	19/23/19	CI
Histogen Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI
North American Morning Briefing : Fed Hawks Hit Stocks	06/23/06	DJ
Histogen to Weigh Strategic Alternatives; Shares Jump After Hours	06/23/06	MT
Histogen to Explore Strategic Alternatives	05/23/05	CI
Histogen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12	CI
North American Morning Briefing : Stock Futures Edge Up Ahead of Looming Catalysts	04/23/04	DJ
Histogen Announces Exclusive Intellectual Property License Agreement with Johns Hopkins University	04/23/04	CI
Histogen Gets US Patent Offering Broad Coverage for Anti-Inflammatory Caspase Inhibitors; Shares Rise Pre-Bell Friday	17/23/17	MT
Top Premarket Gainers	17/23/17	MT
Histogen Inc. Announces Executive Changes	15/23/15	CI
Histogen Inc. Appoints Steven J. Mento, as Chief Executive Officer	15/23/15	CI
Histogen Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	10/23/10	CI
Histogen Inc. Auditor Raises 'Going Concern' Doubt	09/23/09	CI

Chart Histogen Inc.

Duration

Period

More charts

Company Profile

Histogen Inc. is a clinical-stage therapeutics company. The Company is focused on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the bodyâs natural process to restore immune function. Its product candidates include emricasan, CTS-2090 and CTS-2096. It develops emricasan for acute bacterial skin and skin structure infections (ABSSSI) as well evaluating its use for other infectious diseases. Its pipeline also includes novel preclinical product candidates including CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of certain inflammatory diseases. Emricasan is an orally available pan-caspase inhibitor designed to reduce the activities of human caspases, which are enzymes that mediate inflammation and apoptosis. CTS-2090 and CTS-2096 are selective caspase-1 inhibitors targeting inflammasome activation and to treat a variety of inflammation mediated diseases.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
HISTOGEN INC.	-44.75%	7L
VERTEX PHARMACEUTICALS INCORPORATED	+9.83%	12TCr
REGENERON PHARMACEUTICALS, INC.	+10.80%	10TCr
BIONTECH SE	-10.84%	2.27TCr
ARGENX SE	-1.69%	2.18TCr
GENMAB A/S	-10.23%	1.82TCr
WUXI APPTEC CO., LTD.	-41.92%	1.65TCr
BEIGENE, LTD.	-15.11%	1.6TCr
NEUROCRINE BIOSCIENCES, INC.	+6.62%	1.41TCr
SAREPTA THERAPEUTICS, INC.	+17.53%	1.07TCr

Bio Therapeutic Drugs